Use of histone deacetylase inhibitors (HDACis) in pancreatic ductal adenocarcinoma (PDAC): A narrative review Cover

.blurhash-client-img { display: none !important; }

Use of histone deacetylase inhibitors (HDACis) in pancreatic ductal adenocarcinoma (PDAC): A narrative review

Forum of Clinical Oncology

By: Vassiliki Tarara and Evangelos Karamitrousis

Open Access

|Jul 2025

Authors

Vassiliki Tarara

Laboratory of Histology and Embryology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece

Evangelos Karamitrousis

v-a-g-@hotmail.com

Medical Oncology Department, School of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece

DOI: https://doi.org/10.2478/fco-2024-0007 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Submitted on: Oct 6, 2024

|

Accepted on: Dec 23, 2024

|

Published on: Jul 12, 2025

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

genetic transcription,

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology

© 2025 Vassiliki Tarara, Evangelos Karamitrousis, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.